Sponsors (5)
The bill expands a lower‑cost, federally administered public insurance option and drug negotiation authority to improve access and lower consumer costs, but it increases federal spending, shifts market share from private insurers, and may reduce provider payments and state flexibility.
Exchange enrollees and uninsured Americans will gain access to a lower-cost public insurance option beginning in 2027, increasing affordable coverage choices on the market.
Hospitals, clinics, and patients will face fewer administrative barriers and broader network participation because providers who accept Medicare/Medicaid are automatically included in the public option unless they opt out, improving access to care.
People who buy the public option could see lower prescription drug costs if HHS successfully negotiates reduced manufacturer prices under the new authority.
All taxpayers face increased federal spending to start, subsidize, and ultimately repay public option start-up funds over a 10-year period, raising long‑term fiscal exposure.
Private insurers and their small‑business and individual customers may lose enrollees and revenue in Exchanges, potentially reducing competition and consumer choice in some markets.
Hospitals and some specialists could see lower payments if public option reimbursement is tied to Medicare-equivalent rates (or if negotiated rates are lower than commercial rates), pressuring provider finances and potentially access to some services.
Based on analysis of 2 sections of legislative text.
Creates a federally run public health insurance option offered only through ACA Exchanges beginning plan years on/after Jan 1, 2027, with bronze/silver/gold levels and federal rate-setting and data collection.
Introduced January 12, 2026 by Janice D. Schakowsky · Last progress January 12, 2026
Creates a federally administered public health insurance option that HHS must offer through the ACA Exchanges for plan years beginning January 1, 2027. The option must prioritize affordability while maintaining quality and access, be offered only by the HHS Secretary (not private issuers), include bronze/silver/gold levels, follow Exchange and consumer-protection rules, and require data collection and state advisory input to set premiums and reimburse providers.